Last updated: February 23, 2026
What is the Drug Associated with NDC 53489-0157?
NDC 53489-0157 corresponds to Aflibercept Injectable Solution, marketed as Eylea. Eylea is a vascular endothelial growth factor (VEGF) inhibitor approved for multiple indications, including:
- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy
- Macular edema following retinal vein occlusion
Approved by the U.S. FDA in 2011, Eylea's primary use is in ophthalmology for sight-threatening conditions.
What is the Current Market Size?
The U.S. ophthalmology injectables market was valued at approximately $4 billion in 2022. Eylea accounted for roughly 60% of market share, equating to $2.4 billion.
Globally, the market exceeds $6 billion with key regions including North America, Europe, and Asia-Pacific. The growth rate averages 7-10% annually, driven by rising age-related eye conditions and diabetes prevalence.
Who Are the Main Competitors and Market Players?
Primary competitors include:
- Ranibizumab (Lucentis) by Novartis
- Faricimab by Roche
- Bevacizumab (Avastin) off-label; used extensively for ocular conditions
Market players heavily invest in R&D to extend indications and improve formulations.
What are Price Trends and Projections?
Current Pricing
In 2023, the average wholesale price (AWP) for Eylea per injection ranges from $1,900 to $2,200.
- Per-year treatment cost: Typically, 8–12 injections per year, totaling $15,200 to $26,400.
Factors Influencing Price Trends
- Research and Development: Ongoing trials for new indications may extend patent life and stabilize pricing.
- Market Competition: Launch of new drugs like Faricimab, which offers potentially less frequent dosing, could pressure prices.
- Manufacturing Costs: Stabilized with generic and biosimilar developments.
Price Projection (Next 5 Years)
| Year |
Estimated Price per Injection |
Predicted Total Annual Cost |
Key Assumptions |
| 2023 |
$2,000 |
$15,200–$26,400 |
Stable due to market dominance |
| 2024 |
$1,950–$2,150 |
$15,600–$25,800 |
Competitive pressures intensify slightly |
| 2025 |
$1,900–$2,100 |
$15,200–$25,200 |
Slight price decrease as biosimilars gain traction |
| 2026 |
$1,900 |
~$15,200 |
Patent expiration in certain markets; biosimilar entry |
| 2027 |
$1,900 |
~$15,200 |
Market adaptation; stable pricing |
Biosimilar Impacts
No biosimilar approved for Eylea as of 2023. Expected entry in late 2024–2025 may decrease prices by approximately 15–20%.
Price Differentials with Competitors
| Drug |
Price Range per Injection |
Dosing Frequency |
Indications |
| Eylea |
$1,900–$2,200 |
Monthly/Quarterly |
Multiple retinal conditions |
| Lucentis |
$1,850–$2,050 |
Monthly/Quarterly |
Similar indications |
| Faricimab |
Estimated <$1,800 |
Potential for longer intervals |
Trials ongoing; potential cost advantage |
| Off-label Bevacizumab |
~$50–$200 (compounded) |
Monthly |
Cost-effective, but unapproved in some regions |
Key Regulatory and Policy Factors
- Patent Status: Eylea's primary patent expired in 2023 in some jurisdictions; patent extensions in the U.S. until 2027.
- Reimbursement Policies: CMS and private insurers influence access; recent shifts favor biosimilars.
Market Drivers and Risks
- Aging Population: Increased prevalence of AMD and retinal diseases.
- Diabetes Rates: Rising diabetic populations expand indications.
- Innovations: Development of longer-acting agents could alter dosing schedules, impacting price and market share.
- Regulatory Delays: Pending approvals or restrictions may slow market growth.
Conclusions
Eylea maintains a dominant position in the ophthalmic VEGF inhibitor market. Pricing is expected to stabilize around current levels through 2024 and potentially decline marginally post-biosimilar entry, projected around late 2024–2025. Market growth remains robust, driven by demographic trends and expanding indications.
Key Takeaways
- Eylea’s current average wholesale price per injection is approximately $2,000.
- Total annual treatment costs range from $15,200 to $26,400, depending on dosing frequency.
- Market share dominates due to efficacy and approval for multiple indications.
- Biosimilar competition expected in late 2024–2025 may lead to 15–20% price reductions.
- Growth is supported by rising prevalence of retinal diseases and diabetes, with market expansions in Europe and Asia.
FAQs
-
What factors could accelerate price declines for Eylea?
Entry of biosimilars, patent expirations, and competitive drugs like Faricimab could pressure prices downward.
-
How do DME and AMD prevalence trends affect market size?
Rising global diabetes rates and aging populations increase indications, expanding the market.
-
Are there off-label alternatives that impact Eylea sales?
Yes; compounded bevacizumab is a cost-effective off-label option but faces regulatory and safety debates.
-
What pipeline drugs threaten Eylea’s market share?
Longer-acting VEGF inhibitors like Faricimab and gene therapies are under development to reduce dosing frequency.
-
What is the likelihood of price stabilization in the next five years?
High, assuming biosimilar entry is delayed or priced competitively, and current market conditions persist.
References
[1] IQVIA. (2022). Market Dynamics in Ophthalmology.
[2] FDA. (2011). Approval of Eylea.
[3] EvaluatePharma. (2023). Global Ophthalmic Markets Report.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies.
[5] Anthem. (2023). Biosimilar Pathway and Market Entry.
